

PRENATAL DIAGNOSIS

CASES & CLINICAL CHALLENGES

Miriam S. DiMaio

Joyce E. Fox

Maurice J. Mahoney

 WILEY-BLACKWELL

Contents

Cover

Title Page

Copyright

Preface

Chapter 1: Cytogenetic Abnormalities

Chapter 2: Mendelian Inheritance

Introduction to Mendelian Inheritance

Autosomal Dominant Disorders

Autosomal Recessive Disorders

X-Linked disorders

Skeletal Dysplasias

Chapter 3: Non-Mendelian Inheritance

Introduction to Non-Mendelian Inheritance

Mitochondrial Inheritance

Imprinting Disorders

Multifactorial Inheritance

Autism

Chapter 4: First and Second Trimester Screening

Chapter 5: Abnormal Ultrasound Findings

Chapter 6: Common Issues in Prenatal Diagnosis

Introduction to Common Issues in Prenatal Diagnosis

Infertility

Family History

Consanguinity

Non-paternity

Chapter 7: Fetal Infection and Teratogens

Appendix

Index

Prenatal Diagnosis: Cases & Clinical Challenges

Miriam S. DiMaio

MSW

Senior Genetic Counselor

Department of Genetics

Yale University School of Medicine

New Haven, CT

USA

Joyce E. Fox

MD

Chief, Division of Medical Genetics

Schneider Children's Hospital

Professor of Clinical Pediatrics

Albert Einstein College of Medicine

New Hyde Park, NY

USA

Maurice J. Mahoney

MD, JD

Professor of Genetics, Pediatrics, Obstetrics,

Gynecology and Reproductive Sciences

Department of Genetics

Yale University School of Medicine

New Haven, CT

USA

 **WILEY-BLACKWELL**

A John Wiley & Sons, Ltd., Publication

This edition first published 2010, © 2010 by Miriam S. DiMaio, Joyce E. Fox and Maurice J. Mahoney

Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwells publishing program has been merged with Wiley's global Scientific, Technical and Medical business to form Wiley-Blackwell.

Registered office: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade

names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers

should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

ISBN: 9781405191432

A catalogue record for this book is available from the British Library and the Library of Congress.

01 2010

Preface

The advent of mid-trimester amniocentesis in the mid-1960s initiated the era of prenatal diagnosis, a new window into fetal development, health and disease. At that time, the molecular basis of almost all Mendelian disorders was unknown, and few genetic disorders could be tested for prenatally. Initially, fetal diagnosis was largely restricted to chromosomal abnormalities, the few single gene disorders for which molecular or biochemical testing could be performed on amniocytes or amniotic fluid supernatant, and fetal abnormalities that could be identified by ultrasound examination. For some rare disorders, more invasive and riskier testing by fetal blood or skin sampling or fetoscopy could provide information about the fetus.

In the ensuing decades, the explosion of knowledge about the human genome and the molecular pathogenesis of many human diseases, the availability of rapid and highly accurate molecular diagnostic techniques, and the refinement of ultrasound imaging techniques have transformed the field of prenatal diagnosis. Furthermore, maternal serum analyte testing and carrier screening for genetic disorders based on ethnic background, family history or population risk have improved our ability to identify women who are appropriate candidates for diagnostic testing. Next on the horizon will be the diagnosis of fetal disease states using fetal nucleic acids (RNA or DNA) recovered from the maternal circulation. This will markedly alter the current state of prenatal diagnosis and will probably supplant many of our current approaches.

The rapid advances in understanding the molecular basis of human disease have also revealed genetic complexities and mechanisms that were only postulated or even unimagined a generation ago. We now recognize

that for some disorders, different mutations in a single gene can result in markedly disparate clinical presentations. Such disorders, once defined by narrow clinical criteria, are now known to have remarkable variation in their manifestations and age of onset depending on the nature of specific mutation(s) in a single gene. Conversely, the same or similar clinical phenotype can result from mutations in more than one gene. In addition, non-Mendelian mechanisms such as uniparental disomy, trinucleotide repeat expansions, and epigenetic phenomena such as imprinting add another level of complexity when considering an underlying diagnosis.

A problem that often complicates counseling in prenatal diagnosis is the difficulty of making precise predictions about the severity of a disorder that has been diagnosed in utero. This is most common when chromosomal mosaicism is diagnosed in chorionic villi or amniotic fluid and where the possible outcomes range from a disabling condition to normal or near normal. Counseling is also difficult for disorders which have highly variable severity among members of the same family, are of mid-life onset, have a wide range in age of onset, or have reduced penetrance.

For some fetal abnormalities diagnosed on ultrasound examination, there is insufficient information to establish a diagnosis. Questions about the etiology of the fetal abnormalities and their recurrence in subsequent children may have to be resolved after delivery following examination of the baby or by the results of pathological examination that allow a more focused approach to molecular or other testing. Sometimes, however, an underlying diagnosis will not be established, and providing precise information about risk of recurrence is not possible. Empiric data may be available and provide

some guidance. Such data, however, reflect the experience of many families and represent an average risk with some families having a much higher or lower risk.

Exposure to common and unusual clinical problems in prenatal diagnosis should be an integral component in the training of obstetricians, medical geneticists, and genetic counselors. A major shortcoming of such training is that the clinical experience is usually limited to a short period of time in which few complex cases will arise. Physicians and genetic counselors in training are therefore not exposed to the broad range of diagnostic problems and dilemmas that occur in the field of prenatal diagnosis, and they finish their training programs with only superficial clinical exposure. We hope that this book will serve as a supplement to clinical training in the field of prenatal diagnosis.

This book is a product of our own clinical experience over several decades. We have used cases from our own practice and from colleagues elsewhere, some of which have been modified, and present them as vignettes to portray diagnostic problems in prenatal diagnosis. We recognize that our case material reflects predominantly the experience of prenatal diagnosis in the United States and Canada and that medical centers in other parts of the world may have a different experience. Our presentations also reflect, to some degree, protocols that have been developed at our own medical centers.

The format of the book includes a brief synopsis of each case followed by a discussion of the problem, an explanation of the underlying biology, the available testing options, and the results that might be obtained. These cases illustrate approaches to management, including pedigree interpretation, probability, laboratory and technical analysis, and counseling. This book is not a

comprehensive reference about prenatal diagnosis and is not intended to provide in-depth information about the genetic disorders that are discussed. In the interest of presenting cases in a straightforward way, our discussions may lack some of the complexities and nuances that would be found in more comprehensive sources. Some of the cases presented in the book include clinical situations or laboratory results that are rarely encountered in a general prenatal genetics practice. We have chosen to use these unusual cases because they illustrate important concepts about disease causation which have applicability to other more common problems in prenatal diagnosis. As we experience the rapid changes in laboratory methods of genetic diagnosis and in imaging technology, it is easy to predict that diagnostic approaches described herein will become outdated and replaced by newer methods.

The cases emphasize three types of clinical problems which are currently the primary focus of prenatal diagnosis: chromosomal abnormalities, Mendelian disorders, and fetal structural abnormalities that can be diagnosed by ultrasound examination. Multifactorial disorders, other than those associated with structural birth defects, are neglected because their etiology is, at present, not well understood. As our understanding of the molecular and other bases of this class of disorders increases, we anticipate that there will be interest in the prenatal diagnosis of severely disabling conditions.

We have not focused on the counseling aspects of prenatal testing and the psychological impact of abnormal test results. Whether to interrupt or continue a pregnancy is one of the most wrenching decisions that a couple can face. Recognition of the different choices that parents make when confronted with the same fetal disease state reinforces the importance of impartial and

non-directive counseling after a diagnosis has been established.

There are excellent web-based resources that are available and provide comprehensive information about the field. Information about many of the genetic disorders which are discussed in this book were obtained from GeneTests, which is a web based medical genetics information resource for health care providers. GeneTests provides authoritative and comprehensive peer reviewed articles that are written by experts in the field and are updated frequently. GeneTests also contains a directory of clinical and research based genetics laboratories worldwide and the genetic disorders for which testing is available. Another indispensable web based resource is Online Mendelian Inheritance in Man(OMIM), an online catalog of Mendelian traits and disorders, now numbering over 12,000 that includes their clinical presentations and underlying molecular and biochemical bases.

Chapter 1

Cytogenetic Abnormalities

Introduction

The diagnosis of a common trisomy by chorionic villus sampling or amniocentesis is the most frequent reason for referral for genetic counseling in the setting of prenatal diagnosis. There is an abundance of information available in the literature about these situations to provide accurate counseling about the spectrum of structural and functional abnormalities that could be present.

This section includes cases which illustrate the challenges in counseling about several of the less common and more vexing results that can arise from prenatal diagnostic testing. Of these, chromosomal mosaicism in chorionic villi or amniotic fluid is among the most troublesome. Prenatally diagnosed chromosomal mosaicism raises the questions of whether the abnormal cell line is also present in the fetus and, if present, whether there will be fetal damage. Although further diagnostic testing can provide more information, the interpretation of additional evaluations is complicated by phenomena such as tissue-specific mosaicism, uniparental disomy, placental mosaicism with adverse effects on the placenta, fetus or both, and the lack of long-term follow-up of surviving children. Another obstacle is that each case is unique; each case has different percentages of abnormal cells in fetal tissues

that make extrapolation from the experience of case reports in the literature problematic.

Structural chromosomal rearrangements also present challenges to providing definitive prognostic information. In this situation, questions about whether the normal functioning of gene(s) has been disrupted by a translocation or inversion cannot be answered satisfactorily with current testing methods. Some rearrangements involving chromosomes which have imprinted genes raise concern about uniparental disomy which must also be addressed.

Cases involving a discrepancy between the phenotypic and chromosomal sex illustrate the possibilities of laboratory error, fetal disease states, and the limitations of ultrasonographic imaging.

Uncertainties about recurrence risks are heightened when a woman has had more than one trisomic conception, raising the possibilities of gonadal mosaicism in a parent or a predisposition to non-disjunction. Finally, when a diagnosis of a trisomic fetus is made by pathologic examination alone (i.e., without karyotypic confirmation), providing definitive information about risk of recurrence is problematic. This section presents cases of both common and rare prenatally diagnosed chromosomal abnormalities to illustrate the counseling dilemmas that can arise.

Common Aneuploidy - Recurrence Risks and Counseling Pitfalls

Case 1 *A 38-year-old woman is referred for chorionic villus sampling; her obstetric history is remarkable for a previous pregnancy which resulted in a stillbirth of a female infant at term. The woman relates that she was told that an evaluation of the baby after delivery*

revealed trisomy 18. The woman described her baby as having clenched hands, bilateral club feet, and an absent stomach noted on a prenatal ultrasonographic examination performed shortly before delivery. The medical records were not available for review at this time.

Once a woman has had a pregnancy with trisomy 18, the risk of recurrence is about 2.5 times the risk predicted by her age at the time of next pregnancy. The risk for other aneuploidy is about 1.8 times her age-related risk after one previous trisomy 18 conception. Hypotheses that have been offered for these increased risks include gonadal mosaicism for a trisomic cell line (when there is a recurrence of the same trisomy) and a higher risk of meiotic non-disjunction (when there is a recurrence of a different trisomy). Because trisomy 18 has a low incidence, even among older women, the risk for recurrence of fetal trisomy 18 for this woman would be about 1 in 230 taking into account her age and her obstetric history. The risk for Down syndrome would be about 1 in 65. Chorionic villus sampling or amniocentesis will provide definitive information about the fetal karyotype. Alternatively, the results of first trimester screening or integrated risk assessment can incorporate the woman's a priori trisomy 18 and trisomy 21 risks based on her history into the risk assessment. Recurrence risks for common aneuploidy are discussed by Warburton *et al.* (2004).

The woman has chorionic villus sampling at 12 weeks' gestation. The karyotype of cultured chorionic villus cells is 46,XY. Ultrasonographic examination performed at 28 weeks' gestation reveals clenched hands, club feet, micrognathia, an absent stomach, and an increased amniotic fluid volume.

The fetal karyotype is normal yet the findings on ultrasonographic examination suggest a recurrence of the abnormalities seen in the patient's stillborn baby. The phenotype of trisomy 18 can sometimes mimic the fetal akinesia deformation sequence, a condition in which multiple joint contractures (arthrogryposis multiplex congenita) are present due to decreased intrauterine fetal movement. Fetal akinesia deformation sequence is an etiologically heterogeneous condition. Causes include underlying abnormalities of the central or peripheral nervous system, of muscle, of connective tissue, intrauterine vascular compromise, maternal disease states, and space constraints within the womb. Although the majority of cases are associated with low recurrence risk, some cases of fetal akinesia deformation sequence are due to an underlying chromosomal abnormality or mutations in a gene coding for inherited disorders with autosomal dominant, autosomal recessive, X-linked, or mitochondrial inheritance.

Review of the patient's medical records is crucial to providing her with as accurate a recurrence risk as possible. Important information which should be established includes whether a chromosomal analysis was performed or whether the diagnosis of trisomy 18 was made based on physical examination alone.

The medical records from the previous pregnancy become available. The term fetus had contractures at all major joints and a small chin. The internal organs were not examined. A skin biopsy was obtained for chromosomal analysis; cells failed to grow in the laboratory and a karyotype could not be obtained. The medical record states that the differential diagnosis included trisomy 18 and the spectrum of disorders which lead to the fetal akinesia deformation sequence.

Relying on the patient's own report is hazardous in this situation. While the patient was told that trisomy 18 was a possible explanation for her baby's abnormalities, she apparently either did not remember or did not understand that other disease states were included in the differential diagnosis. Without documentation that the previous stillbirth had trisomy 18, other diagnostic entities need to be considered.

Referral for genetics evaluation is now indicated. A large number of genetic disorders can lead to the fetal akinesia deformation sequence. An extensive genetic evaluation of the baby after delivery is indicated.

Further questioning of the mother reveals that she and her husband are first cousins.

The history of consanguinity increases the likelihood that an autosomal recessive condition is the underlying basis for the etiology of the fetal abnormalities. This information can help narrow the differential diagnosis and direct the diagnostic evaluation. Even if the mode of inheritance is thought to be secure, the underlying genetic defect present in the family may not be identifiable, due to the genetic heterogeneity of this disorder. The most common autosomal recessive disorder which can present with fetal akinesia is spinal muscular atrophy due to mutations in the *SMN1* gene. The incidence of spinal muscular atrophy varies among different ethnic groups. Homozygosity for deletions of exons 7 and 8 of the *SMN1* gene are found in 95–98% of affected individuals with the remainder being compound heterozygotes for the deletion and a point mutation in the *SMN1* gene.

Analysis of DNA obtained from cultured amniocytes revealed that the fetus is homozygous for deletions of exons 7 and 8 in the *SMN1* gene.

Case 2 *A 30-year-old woman is referred for genetic counseling because she had a sister who reportedly had Down syndrome and died in the newborn period. The karyotype of the sister is not known. No other family members reportedly have Down syndrome. The woman has a healthy brother.*

The risk for having a child with Down syndrome depends on whether the sister had Down syndrome due to trisomy 21, which is the most likely situation, or to an unbalanced inherited chromosomal translocation which may be carried by this patient in the balanced form.

About 95% of cases of Down syndrome are due to trisomy 21. Unaffected siblings of individuals with trisomy 21 Down syndrome do not have an increased risk of having a child with a chromosomal abnormality. About 4% of individuals with Down syndrome have an unbalanced Robertsonian translocation usually involving chromosome 21 and another acrocentric chromosome (13;21, 14;21, 15;21, 21;22, 21;21 translocations). Unbalanced Robertsonian translocations associated with Down syndrome arise de novo in about two-thirds of cases and the rest are inherited from a parent.

Women who carry Robertsonian translocations involving chromosome 21 have a 10–15% chance of having a fetus with Down syndrome who survives into the second trimester or beyond. The risk of a viable fetus with Down syndrome due to an unbalanced Robertsonian translocation involving chromosome 21 is less than 1% when the translocation is transmitted by a father who is a balanced carrier. Although the risk that our patient carries a Robertsonian translocation is small, definitive information is only available by establishing her peripheral blood karyotype. Array CGH (comparative genomic hybridization) would not provide useful information for this woman because this methodology

identifies deletions and duplications of genetic material but does not identify balanced structural rearrangements.

There are some features in a pedigree that heighten concern about a chromosomal rearrangement segregating in a family. These include more than one affected family member with mental retardation and birth defects (or Down syndrome in the case of Robertsonian translocations involving chromosome 21), stillbirths, recurrent pregnancy loss, and subfertility or infertility. These latter problems reflect the decreased viability of chromosomally abnormal conceptuses.

Case 3 *The results of amniocentesis for a 39-year-old woman indicate that the fetus has trisomy 18 (47,XX,+18). Her obstetric history is remarkable for an intrauterine fetal demise at 33 weeks in a fetus who had trisomy 18 diagnosed at 28 weeks' gestation after ultrasonographic examination revealed severe intrauterine growth retardation and congenital heart disease. She was 33 years of age. She also has a healthy son. All pregnancies have been with her husband. No other relatives have had children with birth defects, recurrent miscarriages, or late fetal deaths.*

This is the second conception of a fetus with trisomy 18 in this woman. Understanding the reason for the recurrence and predicting a risk for still another occurrence are both unsatisfactory. The two occurrences could be by chance alone given that the woman is 39 years old and is at significant risk for fetal aneuploidy. A second explanation is low-grade mosaicism for trisomy 18 in one member of the couple. The mosaicism would involve an unknowable percentage of germline

cells (sperm or ova) and might be demonstrable in peripheral blood lymphocytes or other cell types. There are a small number of persons with identified mosaicism reported in the literature. A third hypothesis raises the possibility of some factor (genetic or otherwise) that increases the rate of meiotic non-disjunction.

Further Reading

- 1.** Hook EB, Cross PK, Jackson L *et al.* (1988) Maternal age-specific rate of 47, + 21 and other cytogenetic abnormalities diagnosed in the first trimester of pregnancy in chorionic villus biopsy specimens: comparison with rates expected from observations at amniocentesis. *American Journal of Human Genetics* **42** (6):797-807.
- 2.** Snijders RJM, Holzgreve W, Cuckle H *et al.* (1994) Maternal age-specific risk for trisomies at 9-14 weeks gestation. *Prenatal Diagnosis* **14**:543-552.
- 3.** Snijders RJ, Sundberg K, Holzgreve W *et al.* (1999) Maternal age- and gestation-specific risk for trisomy 21. *Ultrasound in Obstetrics and Gynecology* **13**:167-170.
- 4.** Warburton D, Dallaire L, Thangavelu M *et al.* (2004) Trisomy recurrence: a reconsideration based on North American data. *American Journal of Human Genetics* **75** (3):376-385.

Reciprocal Translocations and Structural Abnormalities

Case 1 *A healthy 39-year-old woman had amniocentesis at 16 weeks' gestation due to maternal age. Her husband is also 39 years old and healthy. The couple has had three early miscarriages without*

information about the chromosomal status of the conceptions. The amniocyte metaphase karyotype revealed an “apparently balanced” translocation between part of the short arm of chromosome 3 and part of the long arm of chromosome 7 [46,XY,t(3;7)(p13.1;q31.2)]. Ultrasonographic examination performed at the time of amniocentesis revealed normal fetal anatomy. The family histories of the patient and her husband were unremarkable for birth defects, mental retardation, classic genetic disease, stillbirths, or miscarriages.

Balanced chromosomal rearrangements are found in a few percent of phenotypically normal individuals who have experienced recurrent spontaneous pregnancy loss. When a woman has had two or three miscarriages, chromosomal analysis of both members of the couple should be performed.

The chromosomal translocation found in the amniotic fluid cells raises concerns about associated damage to the fetus because one or both of the breakpoints could disrupt normal functioning of gene(s) at or near the sites of the breaks. In addition, there might be missing or extra genetic material at the breakpoints that cannot be detected by visual inspection of the chromosomes under the light microscope. An “apparently balanced” chromosomal rearrangement (a translocation or inversion) may therefore actually be associated with duplications or deletions of genetic material. In fact, apparently balanced chromosomal rearrangements are overrepresented in individuals with mental retardation and birth defects, confirming the limitations of routine chromosomal analysis by light microscopy.

A prenatally diagnosed apparently balanced chromosomal rearrangement may have arisen as a de novo event in the sperm or ovum, or may have been

transmitted from either the mother or father who carries the same translocation in their somatic and gonadal tissues. The risk of adverse effects on fetal development will depend on whether the translocation is present constitutionally in one of the parents. Therefore, the next step is to establish the peripheral blood karyotypes of both parents.

Scenario 1 *The father's peripheral blood karyotype appears identical to that of the fetus: [46,XY,t(3p13.1;7q31.2)].*

Inherited chromosomal rearrangements involving two chromosomal breakpoints are not associated with a significantly increased risk of birth defects. In this scenario, we have also found the translocation in the 39-year-old father who is in good health. This provides reassurance that the translocation is unlikely to be disrupting crucial genes in him or to be associated with clinically important extra or missing genetic material.

While we can be reassuring that the fetus is unlikely to suffer clinical consequences as a result of the translocation, there are circumstances where two members of the same family have the same “apparently balanced” chromosomal rearrangement but have discordant phenotypes. It is important to acknowledge these unlikely possibilities and why they might occur.

There are a number of different reasons which could explain how two individuals in the same family with the same apparently balanced translocation would have different phenotypes.

- 1.** The discordant phenotypes could reflect subtle differences in the translocation (i.e., a duplication or deletion) that occurred during meiosis that could not be detected by routine cytogenetic studies.

- 2.** The translocation might have disrupted a recessive gene in the parent which is compensated for by a

normal gene on the chromosomal homolog. For example, in this case, one of the father's breakpoints is at the cystic fibrosis (*CFTR* gene) locus on chromosome 7. If this were the case, the father is unaffected by cystic fibrosis because his other *CFTR* gene (on his homologous chromosome 7) is normal. However, the fetus inherits another chromosome 7 homolog *from his mother*. If the mother's *CFTR* gene on this chromosome has a mutation, the fetus would have cystic fibrosis symptoms after birth due to the presence of two cystic fibrosis mutations.

3. The father is only 39 years old. Whether the gene(s) involved in the breakpoints of his chromosomal translocation are associated with later-onset disorders is not known.

4. Other genetic or epigenetic influences on genes affected by the translocation, e.g., imprinting, may be present.

To assess the risk of cystic fibrosis, *CFTR* gene mutation screening or *CFTR* gene sequencing of the parents and DNA obtained from cultured amniocytes are available, if desired by the couple.

Experience with array CGH in the prenatal diagnosis setting is still limited at the present time. This analysis has the potential to detect chromosomal deletions and insertions that are below the resolution of the metaphase karyotype. Interpretation of array CGH analysis can be complicated by the finding of DNA variants of uncertain clinical importance.

The finding of the translocation in the father also has implications for future pregnancies. The father produces sperm with normal, balanced, and unbalanced amounts of genetic material depending on the segregation of the chromosomes during meiosis. Thus, the couple may face

an increased risk of fertility problems due to the chromosomal translocation.

The fertility problems that may occur when a parent has a balanced chromosomal rearrangement include difficulty with conception and recurrent miscarriage occurring due to chromosomally unbalanced conceptuses arising from the rearrangement found in the father, and the increased risk of segmental uniparental disomy (for discussion of uniparental disomy see section on Robertsonian translocations).

The chance of an unbalanced viable fetus that survives into later pregnancy or after birth is also increased. Predictions about the likelihood of subfertility or chromosomally unbalanced viable conceptions depend on the size of the unbalanced products of the translocation and the reproductive history of the couple. Identification of the translocation in other family members and their reproductive experience may also help with predictions. In addition, there may be “interchromosomal effects” of the translocation during meiosis in which the translocation interferes with normal pairing of other chromosomes, leading to an increased risk of aneuploidy.

Prenatal diagnosis by chorionic villus sampling or amniocentesis can address the risk of a fetus with an unbalanced translocation or with aneuploidy. Preimplantation genetic diagnosis could also be utilized to identify embryos with unbalanced translocations and introduce only chromosomally normal or balanced embryos to the womb.

The translocation in the father may have been inherited from one of his parents or arisen de novo in the sperm or egg with which he was conceived. If one of his parents is also a translocation carrier, each of the father's siblings has a significant chance of carrying the translocation. This information would be important to share with the

father's siblings so they can be counseled about possible fertility problems and an increased risk of birth defects.

Scenario 2 *The karyotypes of both parents are normal. Non-paternity is denied by the patient.*

Prospective identification and follow-up of other pregnancies with apparently balanced de novo chromosomal rearrangements (translocations and inversions) indicates that risks of obvious birth defects are increased two- to threefold over the background risk of 3% faced by the general population. These increased risks presumably represent unbalanced genetic rearrangements that cannot be ascertained by chromosome analysis. There has been no specific pattern of birth defects in the abnormal fetuses and newborns that have been studied. Risks of learning/behavioral difficulties have not been assessed because there is very limited long-term follow-up of children with de novo apparently balanced chromosomal rearrangements. Because structural birth defects are increased, associated neurodevelopmental problems are also likely.

Array CGH of fetal DNA (obtained from cultured amniocytes or chorionic villi) can detect some deletions and duplications of genetic material that are below the resolution of the light microscope. Array CGH may also be necessary on the parents' DNA because interpretation of array CGH analysis can be complicated by the finding of DNA variants of uncertain clinical importance. The turnaround time for obtaining results should influence decisions about whether testing of the parents' samples should be done simultaneously with that of the fetus.

Detailed ultrasonographic examination and fetal echocardiography should be performed to look for anatomic abnormalities in the fetus. It is estimated that about one-third of the defects associated with de novo

chromosomal rearrangements would be detectable by prenatal sonography.

Case 2 *A couple is referred for genetic counseling to discuss the results of amniocentesis. The amniocyte karyotype is 46,XY,del(13)(q12q14). This is an unbalanced chromosomal complement in which there is an interstitial deletion of a proximal segment of the long arm of chromosome 13. Array CGH shows a 13 MB deletion including deletion of the retinoblastoma gene. The peripheral blood karyotypes of both members of the couple are normal.*

Small deletions of the long arm of chromosome 13 are a rare chromosomal finding and there are only a few case reports of affected individuals. The phenotype described from the case reports includes growth retardation, facial dysmorphism (frontal bossing, bulbous tip of the nose, thick lower lip, large ears and lobes), and mild to moderate mental retardation. Hydrocephalus and neurologic abnormalities may also be part of the phenotype. Absence of one copy of the retinoblastoma gene is predictive of significant increase in risk of malignancy.

Risk of recurrence of another child with a chromosome 13q deletion is small, although higher than that for other couples in the general population. The small increase in risk reflects the unlikely possibility that one of the parents carries a chromosomal rearrangement or an interstitial deletion involving chromosome 13 in their gonadal cells. The fetal karyotype could be established by chorionic villus sampling beginning at 10 weeks' gestation in a future pregnancy if the couple desired early prenatal diagnosis. Ultrasonographic examination has little, if any, utility in the diagnosis of this chromosomal abnormality.

Further Reading

1. De Braekeleer M, Dao T-N (1990) Cytogenetic studies in couples experiencing repeated pregnancy losses. *Human Reproduction* **5**:519-528.
2. Gardner RJM, Sutherland GR (2004) *Chromosome Abnormalities and Genetic Counseling*, 3rd edition. Oxford University Press.
3. Warburton D (1991) De novo balanced chromosome rearrangements and extra marker chromosomes identified at prenatal diagnosis: clinical significance and distribution of breakpoints. *American Journal of Human Genetics* **49**:995-1013.

Robertsonian Translocations

Case 1 *A healthy 31-year-old woman is referred for genetic counseling. After having one healthy child, she had three miscarriages in early pregnancy. All her pregnancies have been with the same partner. Her husband's peripheral blood karyotype is normal (46,XY). She has a balanced Robertsonian translocation between chromosomes 14 and 21 [45,XX,der(14q;21q)].*

Constitutional balanced chromosomal rearrangements, which are seen in about 1 in 400 phenotypically normal individuals, are associated with an increased risk of spontaneous pregnancy loss, chromosomally unbalanced liveborns, and occasionally, infertility. Empiric data suggest that after three or more miscarriages, the probability that one member of a couple has a balanced chromosomal rearrangement, either a chromosomal translocation or chromosomal inversion, is 3-5%. Identification of a balanced chromosomal rearrangement in an individual provides the couple with the likely explanation for their fertility problems, forewarns them about the possibility of a liveborn with an unbalanced chromosomal rearrangement, and affords them the

opportunity for preimplantation or prenatal genetic diagnosis.

Robertsonian translocations refer to a specific class of chromosomal rearrangements in which there is fusion of the long arms of two acrocentric chromosomes (chromosomes 13, 14, 15, 21, and 22). Robertsonian translocations can be homologous in which there is fusion of the long arms of the same acrocentric chromosome, or non-homologous, i.e., fusion of the long arms of two different acrocentric chromosomes. Balanced Robertsonian translocations are the most common human chromosomal translocation with an incidence of 1 in 900 ([Table 1.1](#)). About 4% of liveborns with Down syndrome are due to unbalanced Robertsonian translocations involving chromosome 21.

Table 1.1 Robertsonian translocations

Non-homologous Robertsonian translocations			
t(13;14)*	t(14;15)	t(15;21)**	t(21;22)**
t(13;15)	t(14;21)**	t(15;22)	
t(13;21)**	t(14;22)		
t(13;22)			
Homologous Robertsonian translocations			
t(13;13)			
t(14;14)			
t(15;15)			
t(21;21)**			
t(22;22)			

*Most common, **less common, remainder very rare.

The large majority of Robertsonian translocations are between non-homologous acrocentric chromosomes, and the 13;14 Robertsonian translocation is the most common.

The short arm of an acrocentric chromosome is comprised of the satellite, the satellite stalk, and the proximal short arm. The satellite stalk, also known as the

nucleolar organizing region, contains multiple copies of genes coding for ribosomal RNA. An individual with one Robertsonian translocation has only eight satellite stalks instead of the usual ten. However, this reduction is not detrimental although, presumably, a minimum number of stalks with active genes is necessary for normal cellular function.

With rare exceptions, balanced Robertsonian translocations are not associated with adverse effects on health or development. Individuals with balanced Robertsonian translocations do have an increased risk of infertility, recurrent spontaneous abortions, and, depending on the chromosomes involved in the translocation, an increased risk of chromosomally unbalanced viable fetuses and children. These problems occur because the Robertsonian translocation causes abnormal segregation of the chromosomes during meiosis, resulting in gametes with six different possible chromosomal configurations, only two of which are balanced, as shown in [Figure 1.1](#). Thus, at fertilization, the zygote could have an entirely normal chromosomal complement, the balanced translocation, or various combinations of unbalanced products as illustrated in [Figure 1.2](#).

[Figure 1.1](#) Meiotic segregation in the non-homologous Robertsonian translocation carrier.




Figure 1.2 Possible chromosomal complements in a zygote after fertilization with a gamete of a non-homologous Robertsonian translocation carrier.

